Latest news for MorphoSys (OTC:MPSYF) Stock

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Intraday Update

Markets

Movers

Trading Ideas

AAVVF

ACAD

ACLLF

AFGC

ALAC

ALIAF

AMCI

APLT

ASRAF

AUPH

AWON

BRBR

CDAY

CDLX

CGOOF

CMRE

CMTL

CYSM

DCPH

DRETF

DXCM

Eaton Vance Tax-Advantaged Global Dividend

FLXN

FSUGY

FTAI

GBNXF

GEF-B

GLPG

GMICF

HEBT

ICTSF

IMPUY

INCY

INSG

INVU

ITOCY

KNTNF

LGRDY

LYTS

MAIFF

MAKOF

MITSY

MONRY

Morgan Stanley Capital Protected Notes for S&P 500 Index

MPSYF

Nfj Dividend Interest & Premium Strategy Fund

NMGNF

NSVGF

NTIOF

OGFGY

ORKLY

OYST

PFBC

PMNXF

PNFP

POWL

POYYF

PTCT

PWCDF

PWOD

RESI

RTMVY

SAFE

SAVA

SBGSY

SCFLF

SEAC

SGRY

SNEJF

SPWH

SRCL

THOR

TMOL

TTDKY

Stocks That Hit 52-Week Highs On Thursday

ABMBF

AGYS

AJRD

AKRO

AMRK

ANIK

APPN

ARCE

ATEC

ATLC

AURI

AVDR

AVLR

AZPN

BLDR

BMCH

CABGY

CABJF

CAFI

CAHPF

CASY

CECO

CEVA

CHPGF

CIBEY

CLSI

CNMD

CNNE

CSGS

CWST

CYRX

CYTK

DCGD

ECNCF

EIFZF

EMLAF

EMRAF

ENPH

ESLT

EVRG

FBPRM

FIVN

FTDR

GGDVY

GLDLF

GROW

HEI-A

HPGLY

HUBS

IBIDF

INXN

IOTS

IPHI

IRET

ITRI

JRVR

JUBPF

LZAGY

MELI

Stocks That Set New 52-Week Highs Thursday

MorphoSys AG

MorphoSys expects a 5% surge in Monjuvi sales for Q3

I-Mab gains FDA breakthrough tag for kidney disease therapy

Xencor falls after royalty sale to Canada's OMERS

MorphoSys AG 2023 Q3 - Results - Earnings Call Presentation

MorphoSys AG (MOR) Q3 2023 Earnings Call Transcript

MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating)

MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

MorphoSys: Hold Rating Until The Novartis Deal Closes

Incyte: The Worst Has Been Avoided

ABBV

ADAP

APLM

APLMW

ASPHF

AUTL

BEIGF

BGNE

BMYMP

CRTHF

DAWN

DMPWW

DSKYF

DSNKY

GILD

GLAXF

IMAB

IOVA

JBPHF

KTRA

MDNAF

MORF

NVCR

NVSEF

RCUS

REGN

RHHBF

RHHBY

RHHVF

SMMT

SNDX

SNYNF

SPHRF

SPHRY

SRRK

TKPHF

XNCR

Biotech

Press Releases

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Earnings

Invitation to MorphoSys' Third Quarter and First Nine Months 2023  Financial Results Conference Call on November 16, 2023

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Events

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

MorphoSys

News

Latest news for MorphoSys (OTC:MPSYF) Stock

Thursday, December 05, 2019

Thursday, August 08, 2019